<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="cam41388-tbl-0004" xml:lang="en" orientation="portrait" position="float">
 <label>Table 4</label>
 <caption>
  <p>Overview of treatment‐emergent adverse events (safety population)</p>
 </caption>
 <table frame="hsides" rules="groups">
  <col style="border-right:solid 1px #000000" span="1"/>
  <col style="border-right:solid 1px #000000" span="1"/>
  <col style="border-right:solid 1px #000000" span="1"/>
  <col style="border-right:solid 1px #000000" span="1"/>
  <col style="border-right:solid 1px #000000" span="1"/>
  <thead valign="top">
   <tr style="border-bottom:solid 1px #000000">
    <th align="left" rowspan="2" valign="top" colspan="1">Preferred term</th>
    <th align="left" colspan="3" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Rolontis dose</th>
    <th align="left" rowspan="2" valign="top" colspan="1">Pegfilgrastim 6 mg (
     <italic>n</italic> = 36) 
     <italic>n</italic> (%)
    </th>
   </tr>
   <tr style="border-bottom:solid 1px #000000">
    <th align="left" valign="top" rowspan="1" colspan="1">45 
     <italic>μ</italic>g/kg (
     <italic>n</italic> = 39) 
     <italic>n</italic> (%)
    </th>
    <th align="left" valign="top" rowspan="1" colspan="1">135 
     <italic>μ</italic>g/kg (
     <italic>n</italic> = 37) 
     <italic>n</italic> (%)
    </th>
    <th align="left" valign="top" rowspan="1" colspan="1">270 
     <italic>μ</italic>g/kg (
     <italic>n</italic> = 36) 
     <italic>n</italic> (%)
    </th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="left" rowspan="1" colspan="1">Any treatment‐emergent adverse event</td>
    <td align="left" rowspan="1" colspan="1">36 (92)</td>
    <td align="left" rowspan="1" colspan="1">33 (89)</td>
    <td align="left" rowspan="1" colspan="1">33 (92)</td>
    <td align="left" rowspan="1" colspan="1">35 (97)</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Grade 3–4 TEAE</td>
    <td align="left" rowspan="1" colspan="1">24 (62)</td>
    <td align="left" rowspan="1" colspan="1">12 (32)</td>
    <td align="left" rowspan="1" colspan="1">13 (36)</td>
    <td align="left" rowspan="1" colspan="1">12 (33)</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Treatment‐related TEAE</td>
    <td align="left" rowspan="1" colspan="1">20 (51)</td>
    <td align="left" rowspan="1" colspan="1">19 (51)</td>
    <td align="left" rowspan="1" colspan="1">23 (64)</td>
    <td align="left" rowspan="1" colspan="1">21 (58)</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Any Grade 3–4 related TEAE</td>
    <td align="left" rowspan="1" colspan="1">4 (10)</td>
    <td align="left" rowspan="1" colspan="1">3 (8)</td>
    <td align="left" rowspan="1" colspan="1">4 (11)</td>
    <td align="left" rowspan="1" colspan="1">1 (3)</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Discontinuation due to TEAE</td>
    <td align="left" rowspan="1" colspan="1">0</td>
    <td align="left" rowspan="1" colspan="1">2 (5)</td>
    <td align="left" rowspan="1" colspan="1">1 (3)</td>
    <td align="left" rowspan="1" colspan="1">1 (3)</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Any Serious Adverse Event SAE</td>
    <td align="left" rowspan="1" colspan="1">5 (13)</td>
    <td align="left" rowspan="1" colspan="1">4 (11)</td>
    <td align="left" rowspan="1" colspan="1">2 (6)</td>
    <td align="left" rowspan="1" colspan="1">8 (22)</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Any Treatment‐related SAE</td>
    <td align="left" rowspan="1" colspan="1">0</td>
    <td align="left" rowspan="1" colspan="1">0</td>
    <td align="left" rowspan="1" colspan="1">0</td>
    <td align="left" rowspan="1" colspan="1">3 (8)</td>
   </tr>
  </tbody>
 </table>
 <permissions>
  <copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
 </permissions>
</table-wrap>
